<DOC>
	<DOCNO>NCT01410240</DOCNO>
	<brief_summary>The purpose study compare efficacy safety FLOSEAL standard care hemostasis subject undergoing total knee arthroplasty .</brief_summary>
	<brief_title>Efficacy Safety FLOSEAL Hemostasis Total Knee Arthroplasty</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<criteria>Participant 18 80 year age inclusive time screen Participant plan primary unilateral total knee arthroplasty Participant sign informed consent form Participant stable health ( i.e. , able undergo surgery participate followup program base physical examination medical history ) Participant preoperative Hgb level &gt; 10 g/dL If female childbearing potential , participant present negative urine pregnancy test agree employ adequate birth control measure duration study Participant willing able comply requirement protocol Participant previous total partial knee arthroplasty surgery knee within previous 6 month Participant osteonecrosis arthrotomy within last year Participant prior current hardware target knee Participant injection knee : 1 . Steroids within 3 month prior schedule surgery , 2 . Synvisc , Hyalin , etc . within 6 month prior schedule surgery Participant general surgery within 3 month Participant rheumatoid arthritis inflammatory traumatic bone injury knee within 12 month prior schedule surgery Participant allergies product bovine origin Participant history bleeding , platelet , bone marrow disorder Participant donate 1 unit blood donation 3 week prior surgery Participant history coagulation disorder Participant currently take dipyridamole/ASA ( Aggrenox ) and/or enoxaparin ( Lovenox ) Participant treat aspirin Warfarin ( Coumadin ) clopidogrel ( Plavix ) within 7 day prior surgery Participant permit remain without his/her anticoagulant regimen ( e.g . Plavix ) 48 hour postoperatively Participant take nonsteroidal antiinflammatory agent herbal supplement within 7 day surgery Participant history substance abuse ( alcohol , drug ) active smoker Participant liver cirrhosis Participant erythropoietin agonist/stimulating agent within 90 day prior surgery Participant active infection previous history infection affect joint within previous 6 month Participant participate another clinical study involve investigational product ( IP ) device within 30 day prior study enrollment schedule participate another clinical study involve IP device course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>